BB
BBLG.US Bone Biologics Corp
- Market cap
- USD 1.10M
- P/E
- -
- P/B
- 0.23x
- ROE
- -48.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BBLG.US undervalued?
Graham numberThe Graham number of Bone Biologics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bone Biologics Corp fundamental analysis
No fundamental analysis for Bone Biologics Corp yet.
Bone Biologics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications.…
Full company profileBone Biologics Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bone Biologics Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -700.00 | -96.00 | -96.00 | -50.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
| Operating Income | -20.4M | -2.63M | -2.79M | -2.45M | -825K | -1.10M | -3.67M | -9.43M | -4.22M | -3.23M | -3.04M |
| EBITDA | -20.4M | -2.63M | -2.79M | -2.45M | -825K | -804K | -753K | 479K | 107K | -3.11M | -2.94M |
| Net Income | -25.9M | -7.05M | -4.43M | -3.42M | -1.82M | -1.61M | -1.48M | -8.95M | -4.11M | -3.11M | -2.88M |
| EPS | -24,765 | -6,524 | -3,173 | -67 | -36 | -37 | -31 | -34 | -2.71 | -2.65 | -0.77 |
| Balance Sheet | |||||||||||
| Total Assets | 973K | 796K | 1.04M | 30.8K | 0.00 | 6.68M | 8.50M | 3.74M | 3.86M | 5.80M | 6.43M |
| Total Liabilities | 9.61M | 9.19M | 9.64M | 11.9M | 13.7M | 99.9K | 2.55M | 831K | 378K | 419K | 481K |
| Shareholders' Equity | -8.36M | -8.40M | -8.60M | -11.9M | -13.7M | 6.58M | 5.95M | 2.91M | 3.48M | 5.38M | 5.95M |
| Cash & Short-term Investments | 620K | 690K | 955K | 24.1K | 0.00 | 6.68M | 7.54M | 3.03M | 3.33M | 5.33M | 6.09M |
| Total Debt | 8.76M | 8.23M | 9.00M | 11.3M | 11.7M | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -7.33M | -3.33M | -4.10M | -3.25M | -427K | -1.23M | -3.57M | -9.56M | -4.12M | -2.69M | -2.47M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00 | 0.00 | 0.00 |
| Free Cash Flow | -7.33M | -3.33M | -4.10M | -3.25M | -427K | -1.23M | -3.57M | -9.56M | -4.12M | -2.69M | -2.47M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | -24.5% | -25.0% | -307.9% | -118.0% | -57.8% | -48.3% |
| ROA | -2,659.5% | -886.3% | -425.7% | -11,109.8% | - | -24.1% | -17.5% | -239.4% | -106.5% | -53.6% | -44.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Bone Biologics Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 3.21M | 2.12 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:6 on Jun 10, 2025.
Who owns Bone Biologics Corp
- Insiders 0.02%
- Institutions 4.08%
- Public & others 95.90%
- Shares outstanding 3.39M
- Free float 3.39M
Top funds holding BBLG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 7.81K | 0.23% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 656.00 | 0.02% | 0.00% | Sep 2026 |
Top institutions holding BBLG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 23.9K | 1.19% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 1.95K | 0.10% | -52.67% | Jun 2026 |
| SBI Securities Co Ltd | 230.00 | 0.01% | 0.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
Bone Biologics Corp company profile
- Company name
- Bone Biologics Corp
- Ticker
- BBLG.US
- Exchange
- USA Stocks
- Listed since
- Mar 31, 2016
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2
- Fiscal year end
- December
- Address
- 2 Burlington Woods Drive, Burlington, MA, United States, 01803
- Phone
- 781 552 4452
- Website
- bonebiologics.com
About Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Bone Biologics Corp management
2- Mr. Jeffrey FrelickCEO & President · born 1966
- Ms. Deina H. Walsh CPAChief Financial Officer · born 1964